The peculiarity is that the idea of the project came from those affected by the disease, patients and relatives, who, in their endeavours to find a cure got in touch with basic research groups in order to start a long-term project. The GENEFA Platform, in close collaboration with FEDAES and BabelFAmily, started fund-raising efforts in May 2013, and in November signed an agreement with IRB and CMBSO, headed by Joan Guinovart, director of the IRB, and Margarita Salas, president of the “Fundación Severo Ochoa”.

 “The monthly subscriptions of members of the GENEFA Platform form the basis of the funding; however, the organisation has also held a wide range of fund-raising events and activities and has been supported by donations from companies, associations, and relatives and friends of those affected by Friedreich’s ataxia. We are all working hard towards finding a cure and now the collaboration of FARA guarantees the funding required for this purpose,” explains Juan Carlos Baiges, on behalf of the members of the Platform.

The project involves the research groups headed by Javier Díaz-Nido at the CBMSO, an international expert in gene therapy and Friedreich’s ataxia, and Ernest Giralt at IRB, an international authority on the design of transporters, such as nanoparticles, that can carry drugs into the brain and thus overcome the blood-brain barrier. Patients with this ataxia inherit a mutated version of the frataxin gene, which causes neurodegeneration. The project seeks to rescue this defect in cells of the central nervous system.

Jennifer Farmer, executive director of FARA, explains "when you are working on a rare disease, critical resources, such as funding, are quite small so it is imperative that FARA and other global groups with an interest in supporting and advancing research in Friedreich’s ataxiawork together". "We can't afford to duplicate effort or compete."She goes on to add that “we are proud to give our support to the solid scientific project led by doctors Díaz-Nido and Giralt to identify new therapies and at the same time to strike up an alliance with patients in Spain.”

To find out more about the gene therapy project read the news article:

Patients and scientists join forces to tackle Friedreich’s ataxia (14 November 2013)

Information about the organisations involved:

TheFriedreich’s Ataxia Research Alliance (FARA) is a public, non-profit organisation based in the United States dedicated to curing Friedreich’s Ataxia (FA) through research.FARA grants and programs provide support for basic and translational FA research, pharmaceutical/ biotech drug development, clinical trials, and scientific conferences. www.curefa.org

GENEFA, Platform for a Friedreich's Ataxia cure - Research on gene therapy, was set up in March 2013 by a group of people affected by the disease (patients, relatives and friends). It is a non-profit volunteer-based organisation that seeks to support research efforts into finding a cure for Friedreich’s ataxia. www.genefa.org

The Spanish Federation of Ataxias(FEDAES) is a non-profit organisation that encompasses various regional associations and forms part of other national and European federations. It seeks to promote research into ataxias. It includes and supports the GENEFA Platform, in one of its many endeavours to further efforts to improve the treatment of ataxia. www.fedaes.org

BabelFAmily is a non-profit organization based in Spain. It is formed by an international group of volunteers that unite skills to support the greater FA community of patients, doctors, researchers, scientists and associations in their mission to find treatments and a cure for Friedreich’s ataxia. www.babelfamily.org/en/

INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB) is one of eight centres in Spain to be first recognised as a “Severo Ochoa Centre of Excellence” by the Spanish government. The 23 groups hosted by the institute are devoted to basic and applied research with the common goal of conducting multidisciplinary projects that address important biomedical problems affecting our society. The institute is home to approximately 440 employees from 38 countries. www.irbbarcelona.org/ @IRBBarcelona / www.facebook.com/irbbarcelona

CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA (CBMSO) was founded in 1975 as a mixed centre between the “Universidad Autónoma de Madrid” (UAM) and Spanish National Research Council (CSIC) with the mission to promote research of excellence in Molecular Biology. Its current facilities, a new building on the Cantoblanco campus of the UAM, were opened in January 2008. The CMBSO comprises over 70 groups devoted to various aspects of biomedical and organised into 5 departments. The Severo Ochoa Foundation (FSO) furthers research efforts in the field of Molecular Biology, especially with regard to CBMSO but also throughout Spain. http://www.cbm.uam.es/

http://www.fsochoa.es/

More information:

Sònia Armengou. Press Officer. IRB Barcelona. +34 93 403 72 55 / +34 618 294 070

This email address is being protected from spambots. You need JavaScript enabled to view it.

The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!

https://www.amazon.com/Legacy-Marie-Schlau-collective-Friedreichs-ebook/dp/B01N28AFWZ

 

Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

https://www.irbbarcelona.org/en/news/international-patient-advocates-partner-to-fund-spanish-gene-therapy-project-to-treat

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:

https://www.irbbarcelona.org/en/news/new-research-front-to-tackle-friedreichs-ataxia
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.

 

 

Go to top